March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Erythropoietin and Interleukin 8 Levels in the Vitreous Fluid of Non-diabetic Patients and Diabetic Patients with Progressive Stages of Diabetic Retinopathy
Author Affiliations & Notes
  • Nikolaos Trichopoulos
    Ophthalmology, High Country Macula, Retina, & Vitreous, PC, Albuquerque, New Mexico
  • Dip S. Jadav
    Ophthalmology, University of Texas Health Science Center San Antonio, San Antonio, Texas
  • Neeru Kumar
    Ophthalmology, University of Texas Health Science Center San Antonio, San Antonio, Texas
  • Randolph D. Glickman
    Ophthalmology, University of Texas Health Science Center San Antonio, San Antonio, Texas
  • Footnotes
    Commercial Relationships  Nikolaos Trichopoulos, None; Dip S. Jadav, None; Neeru Kumar, None; Randolph D. Glickman, None
  • Footnotes
    Support  Leonard and Shirley Sterling Endowment for Biochemistry Research in the Department of Ophthalmology at the UTHSCSA
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2413. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nikolaos Trichopoulos, Dip S. Jadav, Neeru Kumar, Randolph D. Glickman; Erythropoietin and Interleukin 8 Levels in the Vitreous Fluid of Non-diabetic Patients and Diabetic Patients with Progressive Stages of Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2413.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Erythropoietin (EPO) is reported to have angiogenic activity but its role in retinal neovascularization is not completely understood. Chronic inflammation also contributes to the complications of diabetes. The purpose of this study was to evaluate whether the levels of EPO and pro-inflammatory cytokine interleukin 8 (IL-8) are elevated in the vitreous fluid of patients with diabetic retinopathy (DR).

Methods: : Prospective analysis of undiluted vitreous samples was performed in discarded vitreous fluid of 64 patients undergoing scheduled vitrectomies. Patients with retinal vascular abnormalities other than DR (e.g. central retinal vein occlusion) were excluded. Twenty patients were non-diabetics and 44 had diabetes mellitus (DM). Ten of these 44 DM patients did not have DR, 7 had non-proliferative diabetic retinopathy (NPDR) and 27 had proliferative diabetic retinopathy (PDR) with or without vitreous hemorrhage. All vitreous samples were analyzed for EPO and IL-8 content using enzyme-linked immunosorbent assay kits.

Results: : Average EPO levels were as follows: non-diabetics (n=20): 16.32 ± 16.25 mIU/ml; diabetics with NPDR or no DR (n=17): 32.91 ± 33.25mIU/ml; and diabetics with PDR (n=27): 190.48 ± 138.21 mIU/ml. Average IL-8 levels were: non-diabetics: 22.49 ± 23.77 pg/ml; diabetics with NPDR or no DR): 39.67 ± 69.95 pg/ml; and diabetics with PDR: 47.81 ± 54.01 pg/ml. A Mann-Whitney "U" test was used to compare these differences. The EPO and IL-8 levels of the non-diabetics and the diabetics with NPDR or no DR did not differ significantly from each other (p > 0.05). In contrast, there were significant differences between the EPO and IL-8 levels of the diabetics with PDR and the diabetics with NPDR or no DR (p ≤.001 for EPO and p ≤.04 for IL-8) and the non-diabetics (p ≤.001 for EPO and p ≤.03 for IL-8).

Conclusions: : Our findings suggest that EPO and IL-8 are increasingly elevated as a consequence of the ischemia and inflammation induced by worsening stages of DR. Further studies may elucidate the interaction between these two molecules to show whether inhibition of EPO and IL-8 could provide a new therapeutic strategy in precluding or arresting pathologic angiogenesis and disease progress in DR.

Keywords: diabetic retinopathy • vitreous • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×